Melodi Matrix
Phase 3- Indications
- Breast reconstruction complications, Post-surgical infections
Company intelligence / Profile preview
Melodi Health is conducting a pivotal ARIA IDE clinical trial of its flagship product, the Melodi Matrix—an absorbable mesh that provides soft tissue support and elutes antibiotics to reduce post-surgical infections in women undergoing breast reconstruction after mastectomy. The first patient was enrolled at University of Utah Health in 2024. No FDA-approved soft tissue support products with antibiotic properties currently exist for this indication
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Melodi Health.